Immunotherapy for Multiple Myeloma (IMWG) Source: International Myeloma Working Group Immunotherapy Committee

Immunotherapy for Multiple Myeloma (IMWG) Sequencing Immunotherapy for Multiple Myeloma Source: International Myeloma Working Group Immunotherapy Committee In 2025, the International Myeloma Working Group Immunotherapy Committee published a set of nine consensus recommendations for the optimal sequential use of immunotherapy agents in the treatment of multiple myeloma. These recommendations were developed by a panel of experts based on the current available evidence. •TCRT or CAR-T cell therapy https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •TCE for rapid progression https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Progressive MM alternatives https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611